Barr Allegra approval
Executive Summary
Barr receives first ANDA approval for generic equivalent to Sanofi-Aventis'Allegra 60 mg capsules July 13. Barr maintains it is the first to file an ANDA for fexofenadine and is therefore entitled to a 180-day exclusivity period. Barr remains in litigation with Sanofi in New Jersey district court over five Allegra patents; the firm says the case may go to trial in early 2006. Barr was approved by FDA to market Allegra-D (fexofenadine/pseudoephedrine) generics in April, but has not yet launched the product (1"The Pink Sheet" April 18, 2005, In Brief)...
You may also be interested in...
Teva Launches Generic Allegra “At Risk” Under Barr’s Exclusivity
Barr could take a one-time charge this quarter for estimated liability related to Teva's "at risk" launch of generic Allegra under Barr's exclusivity
Barr Allegra-D generic
Barr is free to launch the first generic version of Sanofi-Aventis' Allegra-D 12 hour tablets (fexofenadine/pseudoephedrine) following final FDA approval announced April 14. A launch would be "at risk" because of ongoing patent litigation. Approval of Barr's ANDA comes shortly after the company and FDA resolved a dispute over the agency's original decision to split the 180-day exclusivity for generic Allegra-D between Barr and Impax. Barr's withdrawal of a Paragraph IV certification against a late-listed Sanofi-Aventis patent (6,399,632) made it eligible for sole exclusivity and nullified the only remaining 30 month stay...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.